Arvinas, Inc. (ARVN) – What Are Analysts Thinking About This Stock?

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $15.18.

Several analysts recently commented on the stock. Wall Street Zen raised shares of Arvinas from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Evercore set a $14.00 target price on shares of Arvinas in a research note on Monday, August 10th. Morgan Stanley set a $10.00 target price on Arvinas in a report on Monday, August 10th. Wedbush raised their price target on Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright started coverage on Arvinas in a report on Tuesday. They set a “buy” rating and a $13.00 target price for the company.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $13 price target, well above the recent share price. The firm’s rating is supportive, though its newly issued forecasts anticipate losses in several future periods. Arvinas Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Arvinas plans to present preliminary Phase 1 data for ARV-393, its investigational BCL6 degrader, at the 2026 American Society of Hematology meeting. The update could provide a clinical catalyst, but the announcement itself does not include trial results. Arvinas to Present Preliminary Clinical Data for ARV-393
• Negative Sentiment: HC Wainwright’s estimates project losses of $2.44 per share in 2027 and $2.70 in 2028, followed by further losses through 2030. Those forecasts highlight the risk of extended unprofitability and may weigh on sentiment despite the firm’s Buy rating. Arvinas Stock Picked Up by Analysts at HC Wainwright

Hedge Funds Weigh In On Arvinas

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARVN. AlphaCentric Advisors LLC lifted its position in Arvinas by 4.9% during the third quarter. AlphaCentric Advisors LLC now owns 32,121 shares of the company’s stock worth $248,000 after buying an additional 1,499 shares during the period. Corient Private Wealth LP lifted its position in Arvinas by 15.9% in the second quarter. Corient Private Wealth LP now owns 11,945 shares of the company’s stock valued at $99,000 after purchasing an additional 1,637 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Arvinas by 16.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,930 shares of the company’s stock valued at $89,000 after purchasing an additional 1,661 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Arvinas during the third quarter worth $26,000. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Arvinas by 11.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 51,923 shares of the company’s stock worth $550,000 after purchasing an additional 5,349 shares during the period. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Trading Down 2.1%

Shares of ARVN stock opened at $6.41 on Monday. The stock has a 50-day moving average of $7.86 and a 200-day moving average of $9.57. Arvinas has a 1-year low of $6.38 and a 1-year high of $14.51. The stock has a market cap of $413.57 million, a price-to-earnings ratio of -26.71 and a beta of 1.81.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, November 3rd. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. Arvinas had a return on equity of 1.91% and a net margin of 2.94%. The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $12.39 million. During the same quarter last year, the business posted ($0.48) earnings per share. The business’s quarterly revenue was down 98.8% compared to the same quarter last year. Sell-side analysts forecast that Arvinas will post 0.14 earnings per share for the current year.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.